JP2016533749A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016533749A5 JP2016533749A5 JP2016537333A JP2016537333A JP2016533749A5 JP 2016533749 A5 JP2016533749 A5 JP 2016533749A5 JP 2016537333 A JP2016537333 A JP 2016537333A JP 2016537333 A JP2016537333 A JP 2016537333A JP 2016533749 A5 JP2016533749 A5 JP 2016533749A5
- Authority
- JP
- Japan
- Prior art keywords
- newcastle disease
- disease virus
- attenuated newcastle
- virus
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002238 attenuated effect Effects 0.000 claims description 59
- 241000711404 Avian avulavirus 1 Species 0.000 claims description 58
- 241000700605 Viruses Species 0.000 claims description 24
- 210000004027 cell Anatomy 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 108020004707 nucleic acids Proteins 0.000 claims description 9
- 102000039446 nucleic acids Human genes 0.000 claims description 9
- 150000007523 nucleic acids Chemical class 0.000 claims description 9
- 210000004881 tumor cell Anatomy 0.000 claims description 9
- 108700019146 Transgenes Proteins 0.000 claims description 7
- 108091033319 polynucleotide Proteins 0.000 claims description 7
- 102000040430 polynucleotide Human genes 0.000 claims description 7
- 239000002157 polynucleotide Substances 0.000 claims description 7
- 108091026890 Coding region Proteins 0.000 claims description 6
- 102000004127 Cytokines Human genes 0.000 claims description 6
- 108090000695 Cytokines Proteins 0.000 claims description 6
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 claims description 5
- 230000007026 protein scission Effects 0.000 claims description 5
- 208000035269 cancer or benign tumor Diseases 0.000 claims description 4
- 108091029795 Intergenic region Proteins 0.000 claims description 3
- 102000019034 Chemokines Human genes 0.000 claims description 2
- 108010012236 Chemokines Proteins 0.000 claims description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 2
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 claims description 2
- 108010065805 Interleukin-12 Proteins 0.000 claims description 2
- 108090000172 Interleukin-15 Proteins 0.000 claims description 2
- 108010002350 Interleukin-2 Proteins 0.000 claims description 2
- 208000010359 Newcastle Disease Diseases 0.000 claims description 2
- 102000046157 human CSF2 Human genes 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 108010074108 interleukin-21 Proteins 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 230000000174 oncolytic effect Effects 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims description 2
- 230000004083 survival effect Effects 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 238000000034 method Methods 0.000 description 13
- 206010009944 Colon cancer Diseases 0.000 description 4
- 241000059175 Pigeon paramyxovirus 1 Species 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 241001353878 Canine parainfluenza virus Species 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 241001559185 Mammalian rubulavirus 5 Species 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 244000309459 oncolytic virus Species 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 230000007918 pathogenicity Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 101150034814 F gene Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101150008820 HN gene Proteins 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361873039P | 2013-09-03 | 2013-09-03 | |
| US61/873,039 | 2013-09-03 | ||
| PCT/EP2014/068619 WO2015032755A1 (en) | 2013-09-03 | 2014-09-02 | Compositions featuring an attenuated newcastle disease virus and methods of use for treating neoplasia |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019129161A Division JP6862500B2 (ja) | 2013-09-03 | 2019-07-11 | 弱毒化ニューカッスル病ウイルスを特徴とする組成物並びに新生物を治療するための使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016533749A JP2016533749A (ja) | 2016-11-04 |
| JP2016533749A5 true JP2016533749A5 (enExample) | 2017-10-12 |
| JP6557234B2 JP6557234B2 (ja) | 2019-08-07 |
Family
ID=51492938
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016537333A Active JP6557234B2 (ja) | 2013-09-03 | 2014-09-02 | 弱毒化ニューカッスル病ウイルスを特徴とする組成物並びに新生物を治療するための使用方法 |
| JP2019129161A Expired - Fee Related JP6862500B2 (ja) | 2013-09-03 | 2019-07-11 | 弱毒化ニューカッスル病ウイルスを特徴とする組成物並びに新生物を治療するための使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019129161A Expired - Fee Related JP6862500B2 (ja) | 2013-09-03 | 2019-07-11 | 弱毒化ニューカッスル病ウイルスを特徴とする組成物並びに新生物を治療するための使用方法 |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US10519426B2 (enExample) |
| EP (3) | EP4101457A1 (enExample) |
| JP (2) | JP6557234B2 (enExample) |
| KR (2) | KR102285894B1 (enExample) |
| CN (2) | CN106163532B (enExample) |
| AU (2) | AU2014317215C1 (enExample) |
| CA (1) | CA2922071C (enExample) |
| CY (2) | CY1121993T1 (enExample) |
| DK (2) | DK3508209T3 (enExample) |
| EA (2) | EA202191926A3 (enExample) |
| ES (2) | ES2708755T3 (enExample) |
| HK (1) | HK1231393A1 (enExample) |
| HR (2) | HRP20190250T1 (enExample) |
| HU (1) | HUE042382T2 (enExample) |
| LT (2) | LT3041490T (enExample) |
| ME (1) | ME03345B (enExample) |
| MX (2) | MX367768B (enExample) |
| PL (2) | PL3041490T3 (enExample) |
| PT (2) | PT3508209T (enExample) |
| RS (2) | RS58332B1 (enExample) |
| SI (2) | SI3041490T1 (enExample) |
| SM (2) | SMT202200214T1 (enExample) |
| TR (1) | TR201902073T4 (enExample) |
| TW (1) | TWI653334B (enExample) |
| WO (1) | WO2015032755A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2251034B1 (en) | 2005-12-02 | 2018-02-14 | Icahn School of Medicine at Mount Sinai | Chimeric newcastle disease viruses presenting non-native surface proteins and uses thereof |
| ES2550179T3 (es) | 2009-02-05 | 2015-11-05 | Icahn School Of Medicine At Mount Sinai | Virus quiméricos de la enfermedad de Newcastle y usos de los mismos |
| AU2014241843B2 (en) | 2013-03-14 | 2019-05-02 | Icahn School Of Medicine At Mount Sinai | Newcastle disease viruses and uses thereof |
| CN106163532B (zh) * | 2013-09-03 | 2019-12-31 | 免疫医疗有限公司 | 以减毒的新城疫病毒为特征的组合物和用于治疗瘤形成的使用方法 |
| CN107073099B (zh) | 2014-02-27 | 2022-09-27 | 默沙东公司 | 用于治疗癌症的联合方法 |
| EP3288595B1 (en) * | 2015-04-28 | 2020-12-30 | The University Of Georgia Research Foundation, Inc. | Piv5-based amplifying virus-like particles |
| KR102762431B1 (ko) | 2016-01-08 | 2025-02-03 | 레플리뮨 리미티드 | 변형된 항종양 바이러스 |
| EP3246410A1 (en) | 2016-05-19 | 2017-11-22 | Klinikum rechts der Isar der Technischen Universität München | Vsv/ndv hybrid viruses for oncolytic therapy of cancer |
| GB201700350D0 (en) | 2017-01-09 | 2017-02-22 | Replimune Ltd | Altered virus |
| KR101964610B1 (ko) * | 2017-03-13 | 2019-04-03 | 대한민국 | 신규한 종양용해성 바이러스 및 이의 용도 |
| JOP20190256A1 (ar) | 2017-05-12 | 2019-10-28 | Icahn School Med Mount Sinai | فيروسات داء نيوكاسل واستخداماتها |
| CN107254450A (zh) * | 2017-07-20 | 2017-10-17 | 扬州大学 | 克服鸡新城疫母源抗体影响的嵌合新城疫病毒疫苗载体候选株及构建方法 |
| CN108486279A (zh) * | 2017-09-21 | 2018-09-04 | 山东省农业科学院家禽研究所 | 一种基于荧光定量pcr技术检测鸽新城疫病毒的方法 |
| EP3552608A1 (en) * | 2018-04-09 | 2019-10-16 | Rapo Yerape B.H. Ltd | Increased activity of oncoloytic newcastle disease virus |
| JP2021530501A (ja) * | 2018-07-13 | 2021-11-11 | アイカーン スクール オブ メディシン アット マウント サイナイ | 癌の治療のためのａｐｍｖ及びその使用 |
| WO2020037215A1 (en) | 2018-08-17 | 2020-02-20 | Icahn School Of Medicine At Mount Sinai | Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease |
| CN110859968A (zh) * | 2019-11-21 | 2020-03-06 | 四川安可康生物医药有限公司 | 激活对肿瘤的系统免疫反应的基因生物药物 |
| JP2023518295A (ja) * | 2020-03-20 | 2023-04-28 | オルナ セラピューティクス インコーポレイテッド | 環状ｒｎａ組成物及び方法 |
| CN115197949A (zh) * | 2021-04-13 | 2022-10-18 | 江苏康缘瑞翱生物医药科技有限公司 | 一种重组新城疫病毒rNDV-OX40L、其基因组、制备方法及其用途 |
| CA3161532A1 (en) * | 2021-06-03 | 2022-12-03 | University Of Guelph | Engineered newcastle disease virus vector and uses thereof |
| JP2026504603A (ja) * | 2023-02-06 | 2026-02-05 | サイアンバック エルエルシー | 修飾ｐｉｖ５ワクチンベクター：作製方法及び使用方法 |
| KR20250083186A (ko) * | 2023-11-29 | 2025-06-09 | 주식회사 카브 | 재조합 뉴캣슬병 바이러스 벡터를 포함하는 암 치료용 약제학적 조성물 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7724558B1 (en) * | 1999-03-19 | 2010-05-25 | Nec Corporation | Magnetic signal transmission line |
| AU7607900A (en) * | 1999-09-22 | 2001-04-24 | Mayo Foundation For Medical Education And Research | Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family |
| KR100801180B1 (ko) * | 2006-09-26 | 2008-02-05 | 주식회사 고려비엔피 | 약독화된 재조합 뉴캐슬병 바이러스 및 이를 함유하는뉴캐슬병 백신 |
| EP2085092A1 (en) * | 2008-01-29 | 2009-08-05 | Bayer Schering Pharma Aktiengesellschaft | Attenuated oncolytic paramyxoviruses encoding avian cytokines |
| US20090208495A1 (en) | 2008-02-14 | 2009-08-20 | Bayer Schering Pharma Ag | Anti-tumor effective paramyxovirus |
| ES2550179T3 (es) * | 2009-02-05 | 2015-11-05 | Icahn School Of Medicine At Mount Sinai | Virus quiméricos de la enfermedad de Newcastle y usos de los mismos |
| AU2014241843B2 (en) * | 2013-03-14 | 2019-05-02 | Icahn School Of Medicine At Mount Sinai | Newcastle disease viruses and uses thereof |
| CN106163532B (zh) * | 2013-09-03 | 2019-12-31 | 免疫医疗有限公司 | 以减毒的新城疫病毒为特征的组合物和用于治疗瘤形成的使用方法 |
| CN109099045A (zh) * | 2018-10-30 | 2018-12-28 | 浙江斯泰新材料科技股份有限公司 | 防松锁固型螺钉 |
-
2014
- 2014-09-02 CN CN201480048630.4A patent/CN106163532B/zh active Active
- 2014-09-02 MX MX2016002771A patent/MX367768B/es active IP Right Grant
- 2014-09-02 EA EA202191926A patent/EA202191926A3/ru unknown
- 2014-09-02 PL PL14761317T patent/PL3041490T3/pl unknown
- 2014-09-02 US US14/916,102 patent/US10519426B2/en active Active
- 2014-09-02 SM SM20220214T patent/SMT202200214T1/it unknown
- 2014-09-02 DK DK18188565.8T patent/DK3508209T3/da active
- 2014-09-02 DK DK14761317.8T patent/DK3041490T3/en active
- 2014-09-02 TR TR2019/02073T patent/TR201902073T4/tr unknown
- 2014-09-02 PT PT181885658T patent/PT3508209T/pt unknown
- 2014-09-02 ES ES14761317T patent/ES2708755T3/es active Active
- 2014-09-02 PL PL18188565T patent/PL3508209T3/pl unknown
- 2014-09-02 CA CA2922071A patent/CA2922071C/en active Active
- 2014-09-02 KR KR1020167008307A patent/KR102285894B1/ko active Active
- 2014-09-02 RS RS20190176A patent/RS58332B1/sr unknown
- 2014-09-02 AU AU2014317215A patent/AU2014317215C1/en not_active Ceased
- 2014-09-02 WO PCT/EP2014/068619 patent/WO2015032755A1/en not_active Ceased
- 2014-09-02 ES ES18188565T patent/ES2914577T3/es active Active
- 2014-09-02 ME MEP-2019-40A patent/ME03345B/me unknown
- 2014-09-02 HR HRP20190250TT patent/HRP20190250T1/hr unknown
- 2014-09-02 KR KR1020217012332A patent/KR102310692B1/ko active Active
- 2014-09-02 HR HRP20220653TT patent/HRP20220653T1/hr unknown
- 2014-09-02 EP EP22160157.8A patent/EP4101457A1/en not_active Withdrawn
- 2014-09-02 HU HUE14761317A patent/HUE042382T2/hu unknown
- 2014-09-02 SM SM20190094T patent/SMT201900094T1/it unknown
- 2014-09-02 EA EA201690425A patent/EA039404B1/ru unknown
- 2014-09-02 JP JP2016537333A patent/JP6557234B2/ja active Active
- 2014-09-02 EP EP14761317.8A patent/EP3041490B1/en active Active
- 2014-09-02 LT LTEP14761317.8T patent/LT3041490T/lt unknown
- 2014-09-02 RS RS20220481A patent/RS63291B1/sr unknown
- 2014-09-02 HK HK17105137.4A patent/HK1231393A1/zh unknown
- 2014-09-02 EP EP18188565.8A patent/EP3508209B1/en active Active
- 2014-09-02 SI SI201431082T patent/SI3041490T1/sl unknown
- 2014-09-02 CN CN202010064863.0A patent/CN111944767A/zh active Pending
- 2014-09-02 SI SI201431957T patent/SI3508209T1/sl unknown
- 2014-09-02 LT LTEP18188565.8T patent/LT3508209T/lt unknown
- 2014-09-02 PT PT14761317T patent/PT3041490T/pt unknown
- 2014-09-03 TW TW103130466A patent/TWI653334B/zh active
-
2016
- 2016-03-02 MX MX2019010364A patent/MX2019010364A/es unknown
-
2019
- 2019-02-08 CY CY20191100170T patent/CY1121993T1/el unknown
- 2019-06-24 AU AU2019204419A patent/AU2019204419B2/en not_active Ceased
- 2019-07-11 JP JP2019129161A patent/JP6862500B2/ja not_active Expired - Fee Related
- 2019-11-14 US US16/684,241 patent/US11471499B2/en active Active
-
2022
- 2022-05-25 CY CY20221100362T patent/CY1126790T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016533749A5 (enExample) | ||
| JP2019193662A5 (enExample) | ||
| Zamarin et al. | Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions | |
| Janke et al. | Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy | |
| US11471499B2 (en) | Compositions featuring an attenuated newcastle disease virus and methods of use for treating neoplasia | |
| Lundstrom | RNA viruses as tools in gene therapy and vaccine development | |
| JP5296983B2 (ja) | Ｒｎａウイルスが導入された樹状細胞を含む抗癌剤 | |
| Collins et al. | Viral vectors in cancer immunotherapy: which vector for which strategy? | |
| BR112019020001A2 (pt) | linhagens celulares estimuladoras para expansão ex vivo e ativação de células exterminadoras naturais | |
| HRP20231025T1 (hr) | Onkolitički virus vakcinije | |
| JP2014207903A5 (enExample) | ||
| JP2016503029A5 (enExample) | ||
| CN118436692A (zh) | 表达il12的溶瘤弹状病毒 | |
| JP2019508403A5 (enExample) | ||
| JP2016513115A5 (enExample) | ||
| Zhao et al. | Newcastle disease virus: a promising agent for tumour immunotherapy | |
| JP2019533015A5 (enExample) | ||
| JP2015506179A5 (enExample) | ||
| JP2017522326A5 (enExample) | ||
| JP2018522880A5 (enExample) | ||
| Sokke Umeshappa et al. | CD154 and IL-2 signaling of CD4+ T cells play a critical role in multiple phases of CD8+ CTL responses following adenovirus vaccination | |
| Lapp et al. | Viral oncolysis—can insights from measles be transferred to canine distemper virus? | |
| Lorence et al. | Replication-competent, oncolytic Newcastle disease virus for cancer therapy | |
| JP2025188115A (ja) | 新規遺伝子組換えワクシニアウイルス及びその利用 | |
| KR101329348B1 (ko) | 돼지 인터페론 알파-돼지 인터페론 감마를 동시 발현하는 재조합 아데노바이러스 |